Common shares of Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) were approved for trading on the Nasdaq Global Market, effective Nov. 18, under the ticker symbol, LMNL. The shares will continue to trade on the Toronto Stock Exchange under the same symbol.
“Having our common shares traded on NASDAQ represents an important step for Liminal, as we continue to focus on the successful development and commercialization of our proprietary clinical-stage products, including Ryplazim and PBI-4050,” CEO, Kenneth Galbraith, said in a statement.
